BD Diagnostics, a segment of medical technology major
Becton, Dickinson and Company
), has launched the BD ProbeTec Trichomonas vaginalis Qx
Amplified DNA Assay used for the detection of T. vaginalis DNA in
endocervical and vaginal samples as well as neat urine specimens
to aid in the diagnosis of trichomoniasis on the BD Viper System
with XTR Technology.
ALIGN TECH INC (ALGN): Free Stock Analysis
ALPHATEC HLDGS (ATEC): Free Stock Analysis
BECTON DICKINSO (BDX): Free Stock Analysis
STRAUMANN (SAUHF): Get Free Report
To read this article on Zacks.com click here.
The DNA assay has been cleared by the U.S. Food and Drug
Administration (FDA). It is designed for use with the BD Viper
System. It reduces human intervention and associated variables as
well as improves speed to results compared to wet mount
microscopy and culture.
The need for an automated platform such as BD ProbeTec DNA Assay
was awaited due to the increasing prevalence of trichomoniasis
around the world. Globally, more than 180 million cases of this
sexually transmitted infection (STI) have been registered.
Trichomoniasis causes genital inflammation and may lead to
women's susceptibility to HIV infection as well as to HIV
transmission to their sex partners. As a result, detection of
this STI is extremely important for timely and accurate diagnosis
Recently, Becton, Dickinson and Company agreed with U.S. Food and
Drug Administration's (FDA's) proposal to reclassify rapid
influenza detection tests (RIDTs) from Class I devices into Class
II devices. The proposal was examined by FDA's CDRH Microbiology
Devices Advisory Committee Meeting at a hearing in June this
The reclassification will improve the performance of RIDTs. The
reclassified tests will attain at least 90% sensitivity for
influenza A and 80% for influenza B versus viral culture and/or
80% versus polymerase chain reaction (PCR) methods.
Becton, Dickinson and Company reported a marginal 1.3% rise in
third quarter fiscal 2013 adjusted earnings per share from
continuing operations to $1.54, beating the Zacks Consensus
Estimate of $1.47. Revenues went up 3.6% (up 5.1% in constant
currency or CER) to $2,052.7 million, which were marginally ahead
of the Zacks Consensus Estimate of $2,050 million.
BDX reiterated its guidance for fiscal 2013. The company expects
sales growth for fiscal 2013 in the range of 3.5% to 4% (growth
of 5.0% at CER) compared with 4.5% to 5.0% earlier).
Becton, Dickinson and Company also continues to expect reported
earnings per share from continuing operations for fiscal 2013 in
a band of $5.72−$5.75. The projection implies a year-over-year
rise of 6.5%−7.0% (8.5%−9.0% at CER) for fiscal 2013 or
11.0%−11.5% after accounting for the medical device tax
implemented in Jan 2013.
Currently, BDX carries a Zacks Rank #3 (Hold). Other medical
stocks that are worth considering include
STRAUMANN HLD N AKT
) with a Zacks Rank #1 (Strong Buy), and
Alphatec Holdings, Inc.
Align Technology Inc.
), both with a Zacks Rank #2 (Buy).